Luoyang, China | July 26–28, 2025 — SurgSci Medical Ltd. convened its 2025 Mid-Year National Sales Review and Strategic Planning Conference in Luoyang, Henan Province, bringing together sales leadership, marketing teams, and user service representatives from across the country. The three-day event served as a critical checkpoint for evaluating first-half performance and aligning strategic priorities for the remainder of the year.
Under the theme “Strategic Execution · Through Trials to Triumph,” the conference featured comprehensive regional performance reviews, cross-functional discussions on market dynamics, and targeted training sessions designed to enhance product knowledge and operational effectiveness. Participants engaged in collaborative planning to refine customer engagement strategies, strengthen service delivery, and reinforce brand positioning in an increasingly competitive surgical technology landscape.
CEO Bryan Feng delivered a forward-looking address outlining SurgSci’s strategic roadmap, emphasizing clinical validation, market responsiveness, and disciplined execution as key drivers of sustainable growth. Marketing Director David Lv led sessions focused on tactical alignment and resource optimization, ensuring that teams are equipped to meet evolving market demands with agility and precision.
The conference concluded with a reaffirmation of SurgSci’s commitment to innovation, compliance, and customer-centricity. As the company enters the second half of 2025, all departments are unified in their pursuit of excellence—ready to navigate challenges and seize new opportunities across domestic and international markets.
